Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder
Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder
复制标题
DOI：
10.1097/gme.0b013e3182104977
复制
发表时间：
2011-09-01
影响因子：
2.7
通讯作者：
Mishell, Daniel R., Jr.
中科院分区：
文献类型：
--
作者：
Nelken, Rebecca S.;Oezel, Beguem Z.;Mishell, Daniel R., Jr.
目的：本研究的目的是比较超低剂量的雌二醇阴道环与口服奥昔布宁在治疗膀胱过度活动症的绝经后women.Methods的疗效：绝经后妇女膀胱过度活动症从普通妇科门诊招募。参与者随机接受超低剂量雌二醇阴道环或口服奥昔布宁12周。主要结局是24小时内排尿次数减少。次要结果是生活质量问卷调查，阴道pH值水平和阴道成熟指数。31名患者随机接受奥昔布宁治疗，28名患者接受雌二醇阴道环治疗。接受奥昔布宁治疗的妇女平均每天减少3.0次排尿，接受阴道环治疗的妇女平均每天减少4.5次排尿，两组之间没有显著差异。有一个显着的改善，在两组中的泌尿生殖系统的痛苦清单和Injury的影响问卷评分，改善两组之间没有显着差异：超低剂量雌二醇释放阴道环和口服奥昔布宁似乎是同样有效的减少绝经后妇女膀胱过度活动症的每日排尿次数。
Objective: The aim of this study was to compare the efficacy of the ultralow-dose estradiol vaginal ring with that of oral oxybutynin in the treatment of overactive bladder in postmenopausal women.Methods: Postmenopausal women with an overactive bladder were recruited from the general gynecology clinic. Participants were randomized to receive either the ultralow-dose estradiol vaginal ring or oral oxybutynin for 12 weeks. The primary outcome was a decrease in the number of voids in 24 hours. The secondary outcomes were quality-of-life questionnaires, vaginal pH levels, and vaginal maturation index.Results: Fifty-nine women were enrolled. Thirty-one were randomized to receive oxybutynin, whereas 28 received the estradiol vaginal ring. Women who received oxybutynin had a mean decrease of 3.0 voids per day, and women who received the vaginal ring had a mean decrease of 4.5 voids per day, with no significant difference between the groups. There was a significant improvement in Urogenital Distress Inventory and Incontinence Impact Questionnaire scores in both groups, with no significant difference in improvement between the two groups.Conclusions: Ultralow-dose estradiol-releasing vaginal ring and oral oxybutynin seem to be similarly effective in decreasing the number of daily voids in postmenopausal women with overactive bladder.